Hammond Janet MJ has filed 17 insider transactions across 1 company since January 2023.
Most recent transaction: a grant/award of 177000 shares of Atea Pharmaceuticals, Inc. ($AVIR) on January 31, 2026.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | A | Stock Option (Right to Buy) | 177000 | $0.00 | 177,000.0000 | 78,126,796 | 9999.99% | 0.23% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | M | Restricted Stock Units | 11250 | $0.00 | 0.0000 | 78,126,796 | 100.00% | 0.01% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | M | Restricted Stock Units | 46800 | $0.00 | 0.0000 | 78,126,796 | 100.00% | 0.06% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | F | Common Stock | 14136 | $4.24 | 127,665.0000 | 78,126,796 | 9.97% | 0.02% |
| Jan. 31, 2026 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | M | Common Stock | 58050 | $0.00 | 141,801.0000 | 78,126,796 | 69.31% | 0.07% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | M | Common Stock | 46800 | $0.00 | 84,272.0000 | 0 | 124.89% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | A | Common Stock | 11250 | $0.00 | 95,522.0000 | 0 | 13.35% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | F | Common Stock | 14134 | $3.06 | 81,388.0000 | 0 | 14.80% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | M | Restricted Stock Units | 46800 | $0.00 | 46,800.0000 | 0 | 50.00% | 0.00% |
| Jan. 31, 2025 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | A | Restricted Stock Units | 11250 | $0.00 | 11,250.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | A | Stock Option (Right to Buy) | 225200 | $0.00 | 225,200.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | M | Restricted Stock Units | 46800 | $0.00 | 93,600.0000 | 0 | 33.33% | 0.00% |
| Feb. 1, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | S | Common Stock | 14029 | $3.84 | 35,362.0000 | 0 | 28.40% | 0.00% |
| Jan. 31, 2024 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | M | Common Stock | 46800 | $0.00 | 49,391.0000 | 0 | 1806.25% | 0.00% |
| Jan. 31, 2023 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | A | Stock Option (Right to Buy) | 196600 | $0.00 | 196,600.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2023 | Atea Pharmaceuticals, Inc. | $AVIR | Hammond Janet MJ | Chief Development Officer | A | Restricted Stock Units | 140400 | $0.00 | 140,400.0000 | 0 | 9999.99% | 0.00% |